GET DAILY SIGNALSWhy Is Arrowhead Pharmaceuticals (ARWR) Stock Down -15.18% Today?
Key Takeaways
- Direction and magnitude: ARWR shares tumbled 15.18% to $49.33, down from a prior close of $58.16.
- Primary catalyst: A "sell-the-news" reaction to clinical data presented at the American Heart Association's Scientific Sessions, as investors weighed reported benefits against blood-sugar concerns and limited early-stage evidence.
- Secondary drivers: Profit-taking after a recent run-up and a technical breakdown below short-term moving averages that amplified selling pressure.
- Broader context: The decline came amid a risk-off tone for speculative, pre-profit biotech names even as the company's core cardiovascular pipeline posted positive headline results.
- What to watch next: Investors are monitoring upcoming quarterly results, further multiple-dose data, and whether the stock can stabilize near the $50 level.
- For deeper insight into this stock's valuation and outlook, explore the Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see which AI-powered trading strategies are performing best under current market conditions.
Opening Summary
Arrowhead Pharmaceuticals, Inc. (ARWR), a Pasadena, California-based biopharmaceutical company developing RNA interference (RNAi) therapeutics for cardiovascular, metabolic, and other diseases, saw its stock plunge sharply on Monday. Shares fell 15.18% to $49.33, down from a prior close of $58.16, as investors reacted negatively to a slate of clinical data presented over the weekend at the American Heart Association's Scientific Sessions in Chicago. The move marked one of the stock's worst single-session declines in more than a year and came despite what were, on their face, encouraging headline efficacy results.
Clinical Data and a "Sell-the-News" Reaction
The immediate trigger for the selloff was a set of data readouts centered on Arrowhead's cardiovascular franchise. The company reported that its approved triglyceride-lowering drug plozasiran reduced rates of acute pancreatitis by 78% compared with placebo in a pooled analysis of two late-stage studies, with a 91% reduction among participants who had experienced pancreatitis within the prior five years. The company also disclosed early results for ARO-DIMER-PA, an experimental RNAi therapy designed to lower both LDL cholesterol and triglycerides, showing reductions of up to 65% in LDL and up to 78% in triglycerides after a single dose.
Despite the positive top-line numbers, the market treated the news as a disappointment. The ARO-DIMER-PA results came from small dose groups measured against baseline without placebo adjustment, limiting their interpretability, and the LDL reductions landed in a range already achievable with existing therapies. Because ARWR already markets plozasiran, the readout did not appear to represent a meaningful leap beyond the company's own commercial franchise.
Blood-Sugar Concerns Weigh on Sentiment
A key point of investor caution was the safety profile. In the pooled plozasiran analysis, worsening blood-sugar control was reported in 14% of treated participants versus 8.7% of those on placebo — a signal that could matter for the drug's commercial uptake among cardiometabolic patients. Three deaths in the treatment group were assessed as unrelated to the drug, but the glycemic data gave traders a concrete reason to question the risk-reward balance even as efficacy endpoints beat placebo.
Technical Breakdown Amplifies Selling
The fundamental concerns were reinforced by technical pressure. ARWR had been consolidating in a $58 to $61 range in recent sessions, and the decline drove the stock decisively below that band and beneath its short-term moving averages. The breach of what had been support triggered additional momentum-based selling, turning a catalyst-driven pullback into a broader capitulation move. The stock remains well below its 52-week high near $95.49, reached in July, underscoring how far sentiment has deteriorated from the summer peak.
Market Context and Trading Activity
The slide reflected broader caution around clinical-stage and pre-profit biotech names, where valuations are driven largely by pipeline execution rather than current earnings. Arrowhead continues to run significant operating losses and relies heavily on collaboration and milestone payments, leaving the shares sensitive to shifts in risk appetite. While the broader healthcare sector was not the primary driver of Monday's decline, the weakness in ARWR far outpaced the market, indicating company-specific selling rather than a sector-wide rotation.
What Comes Next for ARWR
Looking ahead, investors will be watching for additional multiple-dose data from ARO-DIMER-PA, which the company has indicated will be presented at a future medical meeting, as well as the company's next quarterly earnings release. The path to stabilizing the stock likely depends on whether Arrowhead can demonstrate differentiated, durable efficacy and a clean safety profile as the pipeline advances toward later-stage development. Risks include the ongoing competitive landscape in the cardiovascular RNAi space, continued cash burn, and the possibility that safety signals such as the blood-sugar finding temper commercial enthusiasm for its approved therapy.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots that monitor thousands of tickers, but only the strongest performers under current market conditions are highlighted in the curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving investors a way to see which automated approaches are adapting best to shifting market dynamics. Explore the page to discover strategies that may align with your own research process.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ARWR sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for ARWR moved below the 200-day moving average on October 27, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARWR as a result. In 82 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for ARWR turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 30 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARWR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for ARWR entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +2.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARWR advanced for three days, in 222 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
ARWR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. ARWR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.647) is normal, around the industry mean (3.498). P/E Ratio (-25.509) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (7.940) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (13.812) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARWR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of novel drugs to treat intractable diseases
Industry Biotechnology